SG73999A1 - Hepatitis a virus vaccines - Google Patents

Hepatitis a virus vaccines

Info

Publication number
SG73999A1
SG73999A1 SG1996011170A SG1996011170A SG73999A1 SG 73999 A1 SG73999 A1 SG 73999A1 SG 1996011170 A SG1996011170 A SG 1996011170A SG 1996011170 A SG1996011170 A SG 1996011170A SG 73999 A1 SG73999 A1 SG 73999A1
Authority
SG
Singapore
Prior art keywords
hepatitis
hav
virus vaccines
mrc
growth
Prior art date
Application number
SG1996011170A
Other languages
English (en)
Inventor
Ann W Funkhouser
Hondt Eric D
Robert H Purcell
Suzanne U Emerson
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25485989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG73999(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Publication of SG73999A1 publication Critical patent/SG73999A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG1996011170A 1992-09-18 1993-09-17 Hepatitis a virus vaccines SG73999A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94733892A 1992-09-18 1992-09-18

Publications (1)

Publication Number Publication Date
SG73999A1 true SG73999A1 (en) 2000-07-18

Family

ID=25485989

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996011170A SG73999A1 (en) 1992-09-18 1993-09-17 Hepatitis a virus vaccines

Country Status (14)

Country Link
US (4) US6180110B1 (ja)
EP (1) EP0666751B1 (ja)
JP (1) JP3523646B2 (ja)
AT (1) ATE205536T1 (ja)
AU (1) AU687012B2 (ja)
CA (1) CA2144317C (ja)
DE (1) DE69330758T2 (ja)
DK (1) DK0666751T3 (ja)
ES (1) ES2164074T3 (ja)
HK (1) HK1013667A1 (ja)
NZ (1) NZ256278A (ja)
PT (1) PT666751E (ja)
SG (1) SG73999A1 (ja)
WO (1) WO1994006446A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
AU2005262317B2 (en) * 2004-07-13 2009-07-16 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
CN101356280A (zh) * 2005-06-28 2009-01-28 美利坚合众国政府，由卫生与人类服务部部长代表 野生型甲肝病毒在细胞培养物中的生长
WO2007134250A2 (en) * 2006-05-12 2007-11-22 Goldengate Software, Inc. Method for forming homogeneous from heterogeneous data
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
CN102174477B (zh) * 2010-12-28 2012-11-21 深圳康泰生物制品股份有限公司 甲型肝炎病毒株sh及其二倍体细胞适应方法
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
KR102277089B1 (ko) 2019-12-19 2021-07-14 에스케이바이오사이언스(주) A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4532215A (en) 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175
US4636469A (en) 1982-04-07 1987-01-13 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Isolation of hepatitis A virus strain HM-175
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4620978A (en) 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
US5516630A (en) 1983-09-30 1996-05-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting hepatitis A virus
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
GB8800100D0 (en) * 1988-01-05 1988-02-10 Almond J W Attenuated viruses
EP0542949B1 (en) * 1991-05-08 1998-03-04 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Hepatitis a virus strain, method for the isolation of said virus strains and hepatitis a vaccines

Also Published As

Publication number Publication date
US6180110B1 (en) 2001-01-30
US6680060B2 (en) 2004-01-20
US6423318B1 (en) 2002-07-23
US6113912A (en) 2000-09-05
HK1013667A1 (en) 1999-09-03
DK0666751T3 (da) 2001-11-12
DE69330758T2 (de) 2002-07-04
ATE205536T1 (de) 2001-09-15
JP3523646B2 (ja) 2004-04-26
EP0666751A1 (en) 1995-08-16
AU687012B2 (en) 1998-02-19
DE69330758D1 (de) 2001-10-18
EP0666751A4 (en) 1996-04-24
US20020176869A1 (en) 2002-11-28
ES2164074T3 (es) 2002-02-16
WO1994006446A1 (en) 1994-03-31
CA2144317A1 (en) 1994-03-31
AU4858593A (en) 1994-04-12
EP0666751B1 (en) 2001-09-12
CA2144317C (en) 2004-08-03
JPH08504094A (ja) 1996-05-07
NZ256278A (en) 1996-11-26
PT666751E (pt) 2002-01-30

Similar Documents

Publication Publication Date Title
HK1013667A1 (en) Hepatitis a virus vaccines
NZ226332A (en) Vaccine comprising transmissible gastroenteritis virus of swine for preventing canine coronavirus infection in dogs and process for preparation thereof
CZ203195A3 (en) Method of cultivating a virus of a reproductive and respiratory syndrome of pigs and its use in vaccines
NZ218825A (en) Use of low dosages of interferon as adjuvants for vaccines
AU7763294A (en) Live in ovo vaccine
US4556556A (en) Vaccine for the prevention of vesicular stomatitis virus infection
SE9003198L (sv) Fiskvaccin omfattande en virulent, invasiv bakterie
US4400472A (en) Novel rabies virus strain and a process for its preparation
ATE274579T1 (de) Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
CA2181862A1 (en) Mild newcastle disease virus vaccine
EP0256792A3 (en) Vaccines for fowl colibacillosis
AR009650A1 (es) Mycoplasma synoviae atenuado vivo, su uso, un cultivo microbiologico que lo comprende, una vacuna bacteriana atenuada viva para la proteccion de las aves de corral contra la infeccion por mycoplasma synoviae y un metodo para preparar dicha vacuna.
US3585108A (en) Transmissible gastroenteritis vaccines and methods of producing the same
DK52783A (da) Vaccine indeholdende en ozon-inaktiveret mikroorganisme og fremgangsmaade til fremstilling af en saadan vaccine
Dougan et al. Live bacterial vaccine for delivering antigens to the mammalian immune system.
RU94031386A (ru) Вакцина сухая культуральная против вирусного энтерита гусей и способ профилактики и лечения вирусного энтерита гусей
RU94030087A (ru) Способ получения вакцины против болезни гамборо
Watson Models to study antigenic and virulence properties of Staphylococcus aureus grown under in vivo conditions.
EP0178928A3 (en) Vaccines
GB2129684A (en) A process for the production of an inactivated adjuvated vaccine against Aujeszky disease
RO100317B1 (ro) PROCEDEU DE OBTINERE A UNOR REACTIVI PENTRU STABILIREA TITRULUI DE ANTICORPI îN PSEUDOPESTA AVIARA
ES2168284T3 (es) Una vacuna trivalente bovina intranasal que contiene ibrv, pi3v y brsv vivos y modificados.
RU92011555A (ru) Инактивированная вакцина против инфекционного ринотрахеита крупного рогатого скота
UA38343A (uk) Спосіб моделювання асоційованої форми кандидо-герпетичної інфекції
BG100932A (en) Method for the preparation of cellular cultural inactivated vaccine against fowl pest